# CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

> **NCT01243424** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 6103 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** linagliptin
- **DRUG:** glimepiride
- **DRUG:** linagliptin placebo
- **DRUG:** glimepiride placebo

## Key facts

- **NCT ID:** NCT01243424
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-11
- **Primary completion:** 2018-08-21
- **Final completion:** 2018-08-21
- **Target enrollment:** 6103 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243424, "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01243424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*